[US-헬스케어] 06/25 Wall St. Recap

Eli Lilly (LLY) continues to demonstrate strong market momentum, driven by its robust clinical pipeline and the sustained success of its obesity franchise. The recent disclosure of positive Phase 3 results for Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia (CLL) and advancements in its JAK2 inhibitor candidates underscore the company’s ability to diversify beyond metabolic health. Furthermore, strategic investments in the vaccine market indicate a long-term growth strategy aimed at expanding its therapeutic footprint. Investors are reacting favorably to these developments, reflecting high confidence in the company’s ability to maintain its competitive moat in the biopharmaceutical sector.

Novo Nordisk (NVO) is currently navigating a period of high volatility driven by a mix of operational expansion and regulatory/security headwinds. The successful launch of the oral version of Wegovy in the UAE marks a significant milestone in the company’s international commercial strategy, diversifying its revenue streams beyond the US market. However, the recent data breach involving clinical trial participants introduces potential reputational risk and heightened scrutiny regarding data governance. While the stock has shown sharp price swings, the long-term investment thesis remains anchored in the company’s dominance in the GLP-1 market. Investors should monitor how the company manages the fallout from the data leak while scaling its global supply chain to meet unprecedented demand.

Amgen (AMGN) has demonstrated significant momentum, with a 24% share price appreciation over the past year, leading to valid concerns regarding its current valuation. While the company maintains a robust (dividend) profile and consistent historical performance, the market is now shifting its focus toward future (EPS) and revenue growth trajectories to justify further upside.

Recent analysis of Q1 2026 projections highlights the critical importance of (gross margin) expansion as a primary driver for the $468 price target. Investors should remain cautious; while the long-term outlook remains supported by a solid pipeline, the stock is currently priced for perfection. Future returns will likely depend on the company’s ability to sustain margin improvements amidst competitive pressures and potential (valuation) compression following its recent rally.

UnitedHealth Group (UNH) continues to demonstrate robust financial health, underscored by a recent dividend increase to $2.32 per share and reaffirmed annual guidance. The market’s positive reaction, evidenced by a notable 5.69% price appreciation, reflects investor confidence in the company’s ability to navigate regulatory challenges, such as the insulin oversight settlement. Furthermore, the upward revision of the price target by top-tier analysts at Morgan Stanley signals strong institutional conviction in UNH’s long-term earnings growth and operational resilience. Despite concerns regarding valuation stagnation, the combination of shareholder-friendly capital allocation and favorable analyst sentiment positions the stock for sustained momentum.

Pfizer (PFE) is currently navigating a transitional phase characterized by significant leadership changes and a shifting R&D focus. While the dismissal of the generic price-fixing lawsuit removes a notable legal overhang, the stock continues to face downward pressure as the market recalibrates its valuation post-pandemic. The company’s pivot toward oncology innovation, supported by recent clinical research, provides a potential long-term growth catalyst. However, investors remain cautious regarding the company’s ability to offset declining COVID-19 revenue and effectively compete in the rapidly evolving Chinese pharmaceutical market. The current valuation suggests a potential undervaluation, but sustained upside will depend on the successful execution of its new strategic roadmap under the incoming CFO.